1. Search Result
Search Result
Results for "

DPDS

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

3

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W196803

    Propyl Disulfide; DPDS

    Cytochrome P450 Others
    Dipropyl disulfide is oxidized to dipropyl thiosulfinate (DPDSO) by rat microsomes. Both flavincontaining monooxygenases (FMO) and cytochrome P450 enzymes (CYPs) are involved in dipropyl disulfide oxidation. Dipropyl disulfide forms two metabolites: propylglutathione sulfide conjugate and propylthiol .
    Dipropyl disulfide
  • HY-W012926

    5,6-Dihydrouracil

    Endogenous Metabolite Metabolic Disease
    Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .
    Dihydrouracil
  • HY-W010450

    Endogenous Metabolite Metabolic Disease Cancer
    Thymine, one of the four bases of DNA, is a substrate for rat liver dihydropyrimidine dehydrogenase (DPD), with a Km value of 2.2 μM, Ki of 24 μM (using 5-FU as the DPD substrate), and a specific activity of 0.68 nmol/min/mg .
    Thymine
  • HY-124062
    TAS-114
    3 Publications Verification

    DNA/RNA Synthesis Cancer
    TAS-114 is an orally active dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine .
    TAS-114
  • HY-17469
    Gimeracil
    2 Publications Verification

    Gimestat

    DNA/RNA Synthesis Cancer
    Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil
  • HY-10533

    5-Ethynyluracil; GW776C85

    Biochemical Assay Reagents Cancer
    Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits DPD, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Eniluracil
  • HY-W012926S1

    5,6-Dihydrouracil-d4

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Dihydrouracil-d4 is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .
    Dihydrouracil-d4
  • HY-W014109

    (E)-5-(2-Bromovinyl)uracil; BVU

    DNA/RNA Synthesis Infection
    (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
  • HY-W012926R

    Endogenous Metabolite Metabolic Disease
    Dihydrouracil (Standard)
  • HY-W012926S

    5,6-Dihydrouracil-13C4,15N2

    Endogenous Metabolite Metabolic Disease
    Dihydrouracil- 13C4, 15N2 is the 13C and 15N labeled Dihydrouracil[1]. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[2][3].
    Dihydrouracil-13C4,15N2
  • HY-134160

    5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil

    Nucleoside Antimetabolite/Analog Cancer
    5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.
    5,6-Dihydro-5-Fluorouracil
  • HY-17469S

    Gimestat-13C3,15N

    Isotope-Labeled Compounds Cancer
    Gimeracil- 13C3, 15N (Gimestat- 13C3, 15N) is 13C and 15N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil-13C3,15N
  • HY-14905

    Tri-O-acetyl uridine

    Others Neurological Disease
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .
    Uridine triacetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: